CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?

被引：2
|
作者：
Cutri-French, Clare [1 ]
Nasioudis, Dimitrios [2 ]
George, Erin [3 ]
Tanyi, Janos L. [2 ]
机构：
[1] Univ Penn Hlth Syst, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA
[2] Univ Penn Hlth Syst, Div Gynecol Oncol, Philadelphia, PA 19104 USA
[3] Richard M Schulze Family Fdn Outpatient Ctr, Moffitt Canc Ctr, McKinley Campus,10920 McKinley Dr, Tampa, FL 33612 USA
来源：
DIAGNOSTICS | 2024年 / 14卷 / 08期
关键词：
ovarian cancer; CAR-T therapy; target antigens; mesothelin; CHIMERIC ANTIGEN RECEPTORS; PHASE-I; MESOTHELIN; IMMUNOTHERAPY; EXPRESSION; TARGET; GENERATION; EFFICACY; BINDING; PROTEIN;
D O I：
10.3390/diagnostics14080819
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The success of chimeric antigen receptor T-cell (CAR-T) therapies in the treatment of hematologic malignancies has led to the investigation of their potential in the treatment of solid tumors, including ovarian cancer. While the immunosuppressive microenvironment of ovarian cancer has been a barrier in their implementation, several early phase clinical trials are currently evaluating CAR-T cell therapies targeting mesothelin, folate receptor a, HER2, MUC16, and B7H3. Ongoing challenges include cytokine-associated and "on-target, off-tumor" toxicities, while most common adverse events include cytokine release syndrome, hemophagocytic lymphohistiocytosis/macrophage activation-like syndrome (HLH/MAS), and neurotoxicity. In the present review, we summarize the current status of CAR-T therapy in ovarian cancer and discuss future directions.
引用
收藏
页数：17
相关论文
共 50 条
  • [31] CAR-T therapy of a T-cell cancer successful in a preclinical setting
    不详
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (05) : 1036 - 1036
  • [32] Chimeric antigen receptor T (CAR-T) cell therapy with intrinsic PD-1 blocking for ovarian cancer
    Ukita, Masayo
    Hamanishi, Junzo
    Murakami, Ryusuke
    Abiko, Kaoru
    Baba, Tsukasa
    Mandai, Masaki
    [J]. CANCER SCIENCE, 2018, 109 : 335 - 335
  • [33] CAR-T Cell Therapy for T-Cell Malignancies
    Testa, Ugo
    Chiusolo, Patrizia
    Pelosi, Elvira
    Castelli, Germana
    Leone, Giuseppe
    [J]. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2024, 16 (01)
  • [34] Prospects and challenges of CAR-T in the treatment of ovarian cancer
    Chen, Biqing
    Liu, Jiaqi
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 133
  • [35] ANTI-ALPP CAR-T CELL IMMUNOTHERAPY FOR OVARIAN AND ENDOMETRIAL CANCER
    Li, Si
    Li, Qi-Jing
    Palmer, Nicole
    Guan, Johnny
    Su, Zhenbo
    Alexander, Peter
    Chen, Rui
    Zhao, Lixia
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A223 - A223
  • [36] Anixa to start CAR-T trial for ovarian cancer
    Satyanaryaana, Megha
    [J]. CHEMICAL & ENGINEERING NEWS, 2021, 99 (32) : 15 - 15
  • [37] CAR-T cell combination therapy: the next revolution in cancer treatment
    Al-Haideri, Maysoon
    Tondok, Santalia Banne
    Safa, Salar Hozhabri
    Maleki, Ali Heidarnejad
    Rostami, Samaneh
    Jalil, Abduladheem Turki
    Al-Gazally, Moaed E.
    Alsaikhan, Fahad
    Rizaev, Jasur Alimdjanovich
    Mohammad, Talar Ahmad Merza
    Tahmasebi, Safa
    [J]. CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [38] Teaming up for CAR-T cell therapy
    Waesch, Ralph
    Munder, Markus
    Marks, Reinhard
    [J]. HAEMATOLOGICA, 2019, 104 (12) : 2335 - 2336
  • [39] CAR-T cell therapy for lung cancer: a promising but challenging future
    Zhong, Shupeng
    Cui, Yingqiang
    Liu, Qian
    Chen, Size
    [J]. JOURNAL OF THORACIC DISEASE, 2020, 12 (08) : 4516 - 4521
  • [40] Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy
    Preeti Dabas
    Adithi Danda
    [J]. Medical Oncology, 40
12345